Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 5/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17957971 | 1.00 | MEN1 (0.42) | MEN1KMT2AHDAC6HDAC8TP53 | |
| SCHEMBL17957969 | 1.00 | MEN1 (0.42) | MEN1KMT2AHDAC6HDAC8TP53 | |
| SCHEMBL17991509 | 0.90 | HDAC6 (0.41) | MEN1KMT2AHDAC6HDAC8HCRTR2 | |
| SCHEMBL17957965 | 0.89 | HCRTR2 (0.43) | MEN1KMT2AHDAC6HDAC8TP53 | |
| SCHEMBL17957967 | 0.89 | HCRTR2 (0.43) | MEN1KMT2AHDAC6HDAC8TP53 | |
| SCHEMBL17958081 | 0.89 | HDAC6 (0.42) | MEN1KMT2AHDAC6HDAC8MAOB | |
| SCHEMBL17958040 | 0.89 | HDAC6 (0.42) | MEN1KMT2AHDAC6HDAC8MAOB | |
| SCHEMBL17958042 | 0.89 | HDAC6 (0.42) | MEN1KMT2AHDAC6HDAC8MAOB | |
| SCHEMBL17957578 | 0.89 | HDAC6 (0.43) | MEN1KMT2AHDAC6HDAC8HCRTR2 | |
| SCHEMBL20912073 | 0.89 | HDAC6 (0.43) | MEN1KMT2AHDAC6HDAC8HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428031-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190112280-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112280-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | MEN1 4414/4885KMT2A 62/4885HDAC6 7/4885 |
| US-10428031-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | MEN1 4414/4885KMT2A 62/4885HDAC6 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.